Table 4 Demographic data of patients with and without episodes of bradycardia in the study cohort
Baseline Variables | All patients | Patients with bradycardia | Patients without bradycardia | P value |
|---|---|---|---|---|
Participants (n); male (%) | 85; 69 | 19; 74 | 66; 68 | 0.63 |
Age (y) | \(67.4 \pm 12.3\) | \(71.5 \pm 12.6\) | \(66.2 \pm 12.1\) | 0.18 |
Diabetes duration (y) | \(19.6 \pm 13.2\) | \(17.7 \pm 12.5\) | \(20.2 \pm 13.5\) | 0.56 |
T1DM (%); count (n) | 7.1; 6 | 5.3; 1 | 7.6; 5 | 0.72 |
Mean glucose [mg/dL] | \(165.3 \pm 40.5\) | \(161.1 \pm 26.2\) | \(166.5 \pm 43.9\) | 0.67 |
Mean glucose in low relative glucose tertile [mg/dL] | \(109.2 \pm 30.3\) | \(107.0 \pm 25.6\) | \(109.8 \pm 31.3\) | <0.05 |
Mean glucose in middle relative glucose tertile [mg/dL] | \(156.6 \pm 37.7\) | \(154.7 \pm 29.5\) | \(157.0 \pm 39.4\) | <0.05 |
Mean glucose in high relative glucose tertile [mg/dL] | \(220.8 \pm 59.7\) | \(220.7 \pm 48.6\) | \(220.9 \pm 52.1\) | 0.29 |
Mean eGFR (non-dialysis patients) | \(27.1 \pm 16.8\) | \(37.8 \pm 20.8\) | \(25.1 \pm 15.7\) | <0.05 |
Mean systolic BP (mmHg) | \(138.9 \pm 23.2\) | \(145.8 \pm 22.2\) | \(136.9 \pm 23.3\) | 0.22 |
Mean diastolic BP (mmHg) | \(71.6 \pm 13.4\) | \(69.5 \pm 16.3\) | \(72.2 \pm 12.5\) | 0.54 |
Mean Heart Rate [bpm] | \(73.4 \pm 11.3\) | \(65.9 \pm 10.4\) | \(75.5 \pm 10.7\) | <0.05 |
BMI (kg/\(\hbox {m}^2\)) | \(31.7 \pm 7.7\) | \(32.9 \pm 8.6\) | \(31.3 \pm 7.4\) | 0.54 |
Smoking (%); count (n) | 15.5; 13 | 21.1; 4 | 13.8; 9 | 0.46 |
Hypertension (%); count (n) | 84.5; 72 | 89.5; 17 | 83.1; 55 | 0.52 |
Prior stroke (%); count (n) | 16.5; 14 | 31.6; 6 | 12.1; 8 | <0.05 |
Prior myocardial infarction (%); count (n) | 35.3; 30 | 57.9; 11 | 28.8; 19 | <0.05 |
Atrial fibrillation (%); count (n) | 28.2; 24 | 52.6; 10 | 21.2; 14 | <0.05 |
Coronary artery disease (%); count (n) | 57.7; 49 | 73.7; 14 | 53.0; 35 | 0.14 |
Beta-blocker (%); count (n) | 71.8; 61 | 68.4; 13 | 72.8; 48 | 0.76 |
Antiarrhythmic drugs (%); count (n) | 5.9; 5 | 10.5; 2 | 4.5; 3 | 0.42 |
Antiplatelet therapy (%); count (n) | 63.5; 54 | 63.2; 12 | 63.6; 42 | 0.98 |
Anticoagulation (%); count (n) | 29.4; 25 | 52.6; 10 | 22.7; 15 | <0.05 |
ACE inhibitors (%); count (n) | 49.4; 42 | 42.1; 8 | 51.5; 34 | 0.53 |
Lipid lowering drugs (%); count (n) | 65.9; 56 | 63.2; 12 | 66.7; 44 | 0.81 |
Diuretics (%); count (n) | 76.5; 65 | 73.7; 14 | 77.2; 51 | 0.78 |
